Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
Publishing timestamp: 2024-01-14 08:12:40
Summary
The article discusses the growing market for antibody-drug conjugates (ADCs) in cancer treatment. Researchers believe that ADCs have less toxicity and unwanted effects compared to standard chemotherapy. Companies like Johnson & Johnson, Pfizer, and Merck are making acquisitions and advancements in ADCs, signaling their enthusiasm for this new era of cancer treatment. The market for ADCs is expected to continue growing, with estimates suggesting it could account for a significant portion of the worldwide cancer market. The article also highlights the improvements in ADC technology and the emergence of international drugmakers as effective ADC developers. Additionally, it mentions the motivation for companies to invest in ADCs due to the complexity of the technology and the potential for high prices. Merck and Pfizer are among the companies making significant investments in ADCs to drive growth in their cancer drug offerings.
Sentiment: POSITIVE
Tickers: ADCT, SAN-FR, JNJ, 4568.T-JP, PFE, AZN-GB, GSK, GSK-GB, AMAM, MRK, JPM,
Keywords: sanofi sa, san francisco, adc therapeutics sa, health care industry, astrazeneca plc, gsk plc, jpmorgan drn, science, johnson & johnson, business news, daiichi sankyo co ltd, pfizer inc, ambrx biopharma inc, biotech and pharmaceuticals, business, merck & co inc, breaking news, biotechnology, pharmaceuticals, united states,
Source: https://www.cnbc.com/2024/01/14/cancer-drugs-renewed-interest-in-adcs-will-continue-in-2024.html